ClinicalTrials.gg
CompletedNCT01235520Updated Jun 2, 2015

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

A Phase 3 interventional study of Placebo and RO4917838 in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 122 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
595
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
6th of 16
595 · median 294
Started
2011
with 2 others
Phase 3
6 of 19
none open now
Registered
6th of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2011, is one of 6 in phase 3, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Diagnosis of schizophrenia
  • Clinical stability for 16 weeks (4 months) prior to randomization
  • Antipsychotic treatment stability for the past 12 weeks prior to randomization
  • With the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotic (treatment with a maximum of two antipsychotics)

Exclusion criteria

Exclusion Criteria:

  • Has treatment resistant schizophrenia as judged by the treating physician OR have failed two trials
  • Evidence that patient has uncontrolled or unstable medical disorder (e.g. cardiovascular, renal hepatic, gastrointestinal, hematologic, immunological, neurological, endocrine, metabolic or pulmonary disease)
  • Patient has a (BMI) of \<17 or >40 kg/m2, respectively
  • Diagnosis of mental retardation or severe organic brain syndromes
  • In the investigator's judgment, a significant risk of suicide or violent behavior
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
595 participants (actual)

Study arms

  • Experimental
    1

    Drug: RO4917838

  • Experimental
    2

    Drug: RO4917838

  • Placebo comparator
    3

    Drug: Placebo

Interventions

  • DrugPlacebo

    Oral doses, once a day for 52 weeks

  • Oral dose level 1, once a day for 52 weeks

  • Oral dose level 2, once a day for 52 weeks

06

What researchers measure

Primary outcomes

  1. Positive symptoms factor score assessed by Positive and Negative Syndrome Scale (PANSS)

    Time frame: Change from baseline to Week 12

  2. Safety (incidence of adverse events)

    Time frame: Week 12

Secondary outcomes

  1. Symptom domains of schizophrenia using Positive and Negative Syndrome Scale (PANSS)

    Time frame: Change from baseline to Week 12

  2. Disease improvement on Clinical Global Impression - Improvement (CGI-I) symptoms scale

    Time frame: Change from baseline to Week 12

  3. Disease severity on Clinical Global Impression - Severity (CGI-S) symptoms scale

    Time frame: Change from baseline to Week 12

  4. Safety (incidence of adverse events)

    Time frame: 60 weeks

07

Study locations

122 sites
  • Little Rock, Arkansas 72201, United States
  • Little Rock, Arkansas 72211, United States
  • Buena Park, California 90620, United States
  • Cerritos, California 90703, United States
  • Downey, California 90241, United States
  • La Palma, California 90623, United States
  • Pasadena, California 91106, United States
  • Pico Rivera, California 90660, United States
  • Miami, Florida 33126, United States
  • Miami, Florida 33136, United States
  • Marietta, Georgia 30060, United States
  • Oak Brook, Illinois 60523, United States
  • Iowa City, Iowa 52242, United States
  • Glen Burnie, Maryland 21061, United States
  • Las Vegas, Nevada 89102, United States
  • Toms River, New Jersey 08775, United States
  • Willingboro, New Jersey 08046, United States
  • Albuquerque, New Mexico 87108, United States
  • Brooklyn, New York 11201, United States
  • Fresh Meadows, New York 11366, United States
  • New York, New York 10035, United States
  • Raleigh, North Carolina 27603, United States
  • Cincinnati, Ohio 45206, United States
  • Philadelphia, Pennsylvania 19131, United States
  • Scranton, Pennsylvania 18503, United States
  • Bellaire, Texas 77401, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75243, United States
  • The Woodlands, Texas 77381, United States
  • Kirkland, Washington 98033, United States
  • Buenos Aires, 1425, Argentina
  • Buenos Aires, C1425AHQ, Argentina
  • Ciudad Autonoma Bs As, 1117, Argentina
  • Ciudad Autonoma Bs As, 1405, Argentina
  • Ciudad de Mendoza, 5500, Argentina
  • Cordoba, 5003, Argentina
  • Cordoba, X5009BIN, Argentina
  • La Plata, 1900, Argentina
  • Mendoza, 5500, Argentina
  • Rosario, S2000QJI, Argentina
  • Santiago del Estero, 4200, Argentina
  • Westmead, New South Wales 2145, Australia
  • Clayton, Victoria 3168, Australia
  • Frankston, Victoria 3199, Australia
  • Melbourne, Victoria 3004, Australia
  • Barranquilla, Colombia
  • Bello, Colombia
  • Bogota, Colombia
  • Helsinki, 00250, Finland
  • Kuopio, 70100, Finland
  • Clermont-ferrand, 63000, France
  • Dole, 39100, France
  • Elancourt, 78990, France
  • Marseille, 13005, France
  • Strasbourg, 67091, France
  • Toulon, 83000, France
  • Balassagyarmat, 2660, Hungary
  • Budapest, 1032, Hungary
  • Budapest, 1082, Hungary
  • Budapest, 1135, Hungary
  • Gyor, 9024, Hungary
  • Gyula, 5700, Hungary
  • Ahmedabad, 380006, India
  • Ahmedabad, 380008, India
  • Ahmedabad, 380015, India
  • Bangalore, 560054, India
  • Jaipur, 302017, India
  • Jaipur, 302021, India
  • Kalyan, 421301, India
  • Mangalore, 575001, India
  • Mangalore, 575018, India
  • Nashik, 422101, India
  • Pune, 411030, India
  • Vadodara, 390001, India
  • Busan, 614-735, Korea, Republic of
  • Gwangju, 501-757, Korea, Republic of
  • Gyeonggi-do, 425-707, Korea, Republic of
  • Incheon, 400-711, Korea, Republic of
  • Incheon, 405-760, Korea, Republic of
  • Jeollabuk-do, 561-712, Korea, Republic of
  • Seoul, 110-774, Korea, Republic of
  • Seoul, 136-705, Korea, Republic of
  • Seoul, 150-713, Korea, Republic of
  • Mexico, 05300, Mexico
  • Monterrey, 64000, Mexico
  • Monterrey, 64060, Mexico
  • Monterrey, 64710, Mexico
  • San Luis Potosi, 72818, Mexico
  • Arad, 310022, Romania
  • Bucuresti, 010825, Romania
  • Bucuresti, 041914, Romania
  • Cluj-Napoca, 400012, Romania
  • Lasi, 700282, Romania
  • Oradea, 410154, Romania
  • Sibiu, 550082, Romania
  • Targouiste, 130081, Romania
  • Kemerovo, 650036, Russian Federation
  • Lipetsk, 399313, Russian Federation
  • Moscow Region, 142601, Russian Federation
  • Moscow, 107076, Russian Federation

Showing the first 100 of 122 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry. 2016 Dec;3(12):1115-1128. doi: 10.1016/S2215-0366(16)30344-3. Epub 2016 Nov 2. PubMed 27816567 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2010
First posted
Nov 5, 2010
Start
Jan 2011
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Jun 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01235520
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 5, 2010
Start date
Jan 2011
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Jun 2, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion